Latest from Mayo Clinic Cancer Center

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses genetic abnormalities in multiple myeloma.
 
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses updates to the treatment paradigm of high-risk multiple myeloma in an interview during the 2017 Chemotherapy Foundation Symposium.
Because genetic abnormalities play a role in multiple myeloma, it is important to understand these better to improve outcomes, particularly for high-risk patients, said Shaji K. Kumar, MD. 
Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.
Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses properly managing patients with multiple myeloma.
Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.
Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.
Publication Bottom Border
Border Publication
x